Literature DB >> 14670518

Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS).

Robert L Hubbard1, S Gail Craddock, Jill Anderson.   

Abstract

Followup results from the Drug Abuse Treatment Outcome Studies (DATOS) 1-year and 5-year followups were used to describe the long-term outcomes of drug treatment and to further clarify the relationship between treatment duration and post-treatment outcomes in four treatment modalities: outpatient methadone, long-term residential (LTR), outpatient drug free (ODF), and short-term inpatient. Methods replicating those used in earlier analyses of the DATOS 1-year followup of 2,966 patients admitted to treatment in 1991-1993 and those of the Treatment Outcome Prospective Study patients admitted in 1979-1981 were employed. DATOS is a non-experimental longitudinal study conducted within the natural settings of 96 treatment programs in the U.S.A. The study followed patients during and after treatment at specified periods of time. Prevalence of drug use and behaviors were evaluated for the year prior to treatment; and the post-treatment time frames defined by the 1- and 5-year followups. In addition, the multivariate analytic technique of generalized estimating equations was used to examine the relationship of treatment duration and outcomes across both followups while also controlling for patient characteristics and pretreatment levels of behaviors. The 5-year stratified followup sample included 1,393 of the same individuals in the 1-year followup sample. Analyses were restricted to patients participating in both followups. Reductions in prevalence of cocaine use in the year after treatment (compared to the preadmission year) by patients were associated with longer treatment durations (particularly 6 months or more in LTR and ODF). In addition, reductions in illegal activity and increases in full-time employment were related to treatment stays of 6 months or longer for patients in LTR. The DATOS results from the 1-year and 5-year post-treatment followup combined suggest the stability of outcomes of substance abuse treatment. While results are generally consistent with the full 1-year followup, reduced sample size and bias of the sample toward patients with longer treatment retention may have attenuated the findings.

Entities:  

Mesh:

Year:  2003        PMID: 14670518     DOI: 10.1016/s0740-5472(03)00130-2

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  121 in total

1.  Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Authors:  Cheryl Teruya; Robert P Schwartz; Shannon Gwin Mitchell; Albert L Hasson; Christie Thomas; Samantha H Buoncristiani; Yih-Ing Hser; Katharina Wiest; Allan J Cohen; Naomi Glick; Petra Jacobs; Paul McLaughlin; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Socioeconomic differences in adolescent substance abuse treatment participation and long-term outcomes.

Authors:  Camillia K Lui; Stacy A Sterling; Felicia W Chi; Yun Lu; Cynthia I Campbell
Journal:  Addict Behav       Date:  2017-01-06       Impact factor: 3.913

3.  Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.

Authors:  Melanie S Askari; Silvia S Martins; Pia M Mauro
Journal:  J Subst Abuse Treat       Date:  2020-05-11

4.  Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling
Journal:  Arch Gen Psychiatry       Date:  2011-11-07

5.  Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States.

Authors:  Edmund J Bini; Steven Kritz; Lawrence S Brown; Jim Robinson; Don Alderson; John Rotrosen
Journal:  J Addict Dis       Date:  2011-04

6.  Individual and system influences on waiting time for substance abuse treatment.

Authors:  Carey J A Carr; Jiangmin Xu; Cristina Redko; D Timothy Lane; Richard C Rapp; John Goris; Robert G Carlson
Journal:  J Subst Abuse Treat       Date:  2007-05-23

7.  Patient-centered methadone treatment: a randomized clinical trial.

Authors:  Robert P Schwartz; Sharon M Kelly; Shannon G Mitchell; Jan Gryczynski; Kevin E O'Grady; Devang Gandhi; Yngvild Olsen; Jerome H Jaffe
Journal:  Addiction       Date:  2016-11-10       Impact factor: 6.526

8.  Treatment outcomes for substance use disorder among women of reproductive age in Massachusetts: a population-based approach.

Authors:  Judith Bernstein; Taletha M Derrington; Candice Belanoff; Howard J Cabral; Hermik Babakhanlou-Chase; Hafsatou Diop; Stephen R Evans; Hilary Jacobs; Milton Kotelchuck
Journal:  Drug Alcohol Depend       Date:  2014-12-04       Impact factor: 4.492

9.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15

10.  Change in employment status and cocaine use treatment outcomes: A secondary analysis across six clinical trials.

Authors:  André Q C Miguel; Brian D Kiluk; Corey R Roos; Theresa A Babuscio; Charla Nich; Jair J Mari; Kathleen M Carroll
Journal:  J Subst Abuse Treat       Date:  2019-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.